Announcement on Resolutions of the 11th Session of the 2nd Board of Directors
Release time:
2021-05-20
证券代码:600668 证券简称:尖峰集团 编号:临2021-005
浙江尖峰集团股份有限公司
十一届2次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及《公司章程》的相关规定。
(二)2021年4月13日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2021年4月24日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场方式召开。
(四)公司现有九名董事,全体董事出席了会议并表决。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了《2020年度总经理业务报告》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了《2020年度财务决算报告》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
3、通过了《2020年度利润分配预案》
董事会审议并通过了该预案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于2020年度利润分配预案的公告》(临2021-007)。
该预案将提交股东大会审议。
公司独立董事对该议案发表了独立意见:
(1)我们同意公司以2020年末股本344,083,828股为基数,每10股派发现金红利4.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为137,633,531.20元(含税)。2020年度不进行公积金转增股本。
(2)该利润分配预案是根据公司2020年度实际经营成果及财务状况,结合公司未来业务发展的实际需要而制定。留存未分配利润主要用于满足公司发展的资金需求,有利于公司的持续健康发展,不存在损害股东特别是中小股东权益的情况。我们认为该利润分配预案符合《公司章程》对于利润分配的相关规定,符合公司的实际经营状况。
(3)公司董事会审议通过了上述利润分配预案。我们认为本次会议的召集、召开及审议表决程序符合相关法律、法规及《公司章程》的规定,合法有效;并同意将该预案提交公司2020年年度股东大会审议。
4、通过了《关于聘请公司2021年度审计机构的议案》
董事会审议并通过了该议案。同意继续聘请天健会计师事务所(特殊普通合伙)为公司2021年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
详见《关于聘请公司2021年度审计机构的议案》(临2021-008)。
该议案将提交股东大会审议。
5、通过了《关于为控股子公司提供担保的议案》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于为控股子公司提供担保的公告》(临2021-009)。
本议案需提交股东大会审议。
6、通过了2020年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,2020年度提取中长期激励基金1849.78万元。
表决结果:同意9票、反对0票、弃权0票。
7、通过了《2020年年度报告及其摘要》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2020年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
该报告需提交股东大会审议。
8、通过了《关于召开2020年度股东大会的议案》
董事会审议并通过了该议案。董事会决定于2021年5月28日在浙江省金华市婺江东路88号尖峰大厦召开2020年度股东大会,并提供网络表决方式。
表决结果:同意9票、反对0票、弃权0票
详见《关于召开2020年度股东大会的通知》(临2021-010)。
9、通过了《项目跟投管理办法》
董事会审议并通过了该办法。
表决结果:同意6票、反对0票、弃权0票。董事蒋晓萌先生、虞建红先生、黄金龙先生回避了该议案的表决。
《项目跟投管理办法》详见上海证券交易所网站(www.sse.com.cn)。
10、通过了《关于调整独立董事津贴的议案》
董事会审议并通过了该议案。
依据中国证监会《关于在上市公司建立独立董事制度的指导意见》及《公司章程》 等相关规定,参照上市公司独立董事薪酬平均水平,结合公司实际,拟调整公司独立董事及专家董事津贴至每人每年8万元人民币(含税),自2021年1月1日开始执行,其所涉及的个人所得税由公司代扣代缴。
表决结果:同意9票、反对0票、弃权0票。
详见《关于调整独立董事津贴的公告》(临2021-011)。
该议案需提交股东大会审议。
11、通过了《关于受让金华银行股权的议案》
董事会审议并通过了该议案。
本公司现持有金华银行股份有限公司(以下简称:“金华银行”)4,875.81万股。本次同意公司出资9621.36万元,以2.94元/股的价格受让金华银行股份有限公司工会委员会所持有的金华银行股权3,272.57万股,本次股权受让完成后,公司将持有金华银行8,148.38万股。该股权受让事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
表决结果:同意9票、反对0票、弃权0票。
12、通过了《2020年度内部控制评价报告》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
《2020年度内部控制评价报告》详见上海证券交易所网站(www.sse.com.cn)。
13、通过了《董事会审计委员会2020年度履职报告》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
《董事会审计委员会2020年度履职报告》详见上海证券交易所网站(www.sse.com.cn)。
14、通过了《独立董事2020年度述职报告》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
《独立董事2020年度述职报告》详见上海证券交易所网站(www.sse.com.cn)。
独立董事将向股东大会报告。
15、通过了《2020年度董事会报告》
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的其他独立意见:
此外,公司独立董事对上述4、关于聘请公司2021年度审计机构的议案;5、关于为控股子公司提供担保的议案;6、2020年度《中长期激励基金计提方案》;9、《项目跟投管理办法》;10、关于调整独立董事津贴的议案五项决议都发表了同意的独立意见,认为:上述董事会决议的形成符合《公司法》、《公司章程》等有关规定,没有损害中小股东的利益。
三、相关附件
1、公司第十一届董事会第2次会议决议
2、公司独立董事对上述相关事项的独立董事意见
特此公告
浙江尖峰集团股份有限公司
董 事 会
二〇二一年四月二十七日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31